{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:17:52Z","timestamp":1793402272787,"version":"4.5.0"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:00:00Z","timestamp":1615507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Lack of demonstrable mutations affecting\n                    <jats:italic>JAK2, CALR<\/jats:italic>\n                    , or\n                    <jats:italic>MPL<\/jats:italic>\n                    driver genes within the spectrum of\n                    <jats:italic>BCR-ABL1<\/jats:italic>\n                    -negative myeloproliferative neoplasms (MPNs) is currently referred to as a triple-negative genotype, which is found in about 10% of patients with essential thrombocythemia (ET) and 5\u201310% of those with primary myelofibrosis (PMF). Very few papers are presently available on triple-negative ET, which is basically described as an indolent disease, differently from triple-negative PMF, which is an aggressive myeloid neoplasm, with a significantly higher risk of leukemic evolution. The aim of the present study was to evaluate the bone marrow morphology and the clinical-laboratory parameters of triple-negative ET patients, as well as to determine their molecular profile using next-generation sequencing (NGS) to identify any potential clonal biomarkers. We evaluated a single-center series of 40 triple-negative ET patients, diagnosed according to the 2017 WHO classification criteria and regularly followed up at the Hematology Unit of our Institution, between January 1983 and January 2019. In all patients, NGS was performed using the Illumina Ampliseq Myeloid Panel; morphological and immunohistochemical features of the bone marrow trephine biopsies were also thoroughly reviewed. Nucleotide variants were detected in 35 out of 40 patients. In detail, 29 subjects harbored one or two variants and six cases showed three or more concomitant nucleotide changes. The most frequent sequence variants involved the\n                    <jats:italic>TET2<\/jats:italic>\n                    gene (55.0%), followed by\n                    <jats:italic>KIT<\/jats:italic>\n                    (27.5%). Histologically, most of the cases displayed a classical ET morphology. Interestingly, prevalent megakaryocytes morphology was more frequently polymorphic with a mixture of giant megakaryocytes with hyperlobulated nuclei, normal and small sized maturing elements, and naked nuclei. Finally, in five cases a mild degree of reticulin fibrosis (MF-1) was evident together with an increase in the micro-vessel density. By means of NGS we were able to identify nucleotide variants in most cases, thus we suggest that a sizeable proportion of triple-negative ET patients do have a clonal disease. In analogy with driver genes-mutated MPNs, these observations may prevent issues arising concerning triple-negative ET treatment, especially when a cytoreductive therapy may be warranted.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2021.637116","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T02:10:52Z","timestamp":1615515052000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":34,"title":["Triple-Negative Essential Thrombocythemia: Clinical-Pathological and Molecular Features. A Single-Center Cohort Study"],"prefix":"10.3389","volume":"11","author":[{"given":"Daniele","family":"Cattaneo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio Alberto","family":"Croci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Bucelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Tabano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Giulia","family":"Cannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Gaudioso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Barbanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kordelia","family":"Barbullushi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Fermo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Fabris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Baldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Gianelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Iurlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.leukres.2012.08.011","article-title":"Myeloproliferative neoplasms 2012: the John M. Bennett 80th birthday anniversary lecture","volume":"36","author":"Tefferi","year":"2012","journal-title":"Leuk Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/ejh.12256","article-title":"Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union","volume":"92","author":"Moulard","year":"2014","journal-title":"Eur J Haematol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/bjh.14061","article-title":"Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic\/myeloproliferative neoplasms in the United States, 2001-12","volume":"174","author":"Srour","year":"2016","journal-title":"Br J Haematol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"Gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet."},{"key":"B8","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1097\/PPO.0b013e318159467b","article-title":"JAK2 mutations and clinical practice in myeloproliferative neoplasms","volume":"13","author":"Tefferi","year":"2007","journal-title":"Cancer J."},{"key":"B9","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrc2210","article-title":"Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders","volume":"7","author":"Levine","year":"2007","journal-title":"Nat Rev Cancer."},{"key":"B10","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia","volume":"110","author":"Vannucchi","year":"2007","journal-title":"Blood."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/leu.2008.113","article-title":"Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal","volume":"22","author":"Vannucchi","year":"2008","journal-title":"Leukemia."},{"key":"B12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3324\/haematol.2008.001271","article-title":"Clinical relevance of JAK2 (V617F) mutant allele burden","volume":"94","author":"Passamonti","year":"2009","journal-title":"Haematologica."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.exphem.2009.06.006","article-title":"JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera","volume":"37","author":"Carobbio","year":"2009","journal-title":"Exp Hematol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/ajh.26008","article-title":"Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management","volume":"95","author":"Tefferi","year":"2020","journal-title":"Am J Hematol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Eng J Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Eng J Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/ejh.12389","article-title":"Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history","volume":"94","author":"Gangat","year":"2015","journal-title":"Eur J Haematol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocytemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","article-title":"Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia","volume":"123","author":"Rotunno","year":"2014","journal-title":"Blood."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1007\/s00277-014-2151-8","article-title":"Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia","volume":"93","author":"Chen","year":"2014","journal-title":"Ann Hematol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"E121","DOI":"10.1002\/ajh.23743","article-title":"Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients","volume":"89","author":"Tefferi","year":"2014","journal-title":"Am J Hematol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1182\/blood-2015-07-661835","article-title":"Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms","volume":"127","author":"Milosevic","year":"2016","journal-title":"Blood."},{"key":"B25","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1182\/blood-2015-07-661983","article-title":"Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients","volume":"127","author":"Cabagnols","year":"2016","journal-title":"Blood."},{"key":"B26","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1182\/blood-2016-10-695957","article-title":"Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms","volume":"129","author":"Rumi","year":"2017","journal-title":"Blood."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia."},{"key":"B28","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/MOH.0000000000000406","article-title":"Driver mutations in primary myelofibrosis and their implications","volume":"25","author":"Szuber","year":"2018","journal-title":"Curr Opin Hematol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1046\/j.1365-2141.2002.03688.x","article-title":"Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients","volume":"118","author":"Cervantes","year":"2002","journal-title":"Br J Haematol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.3324\/haematol.13346","article-title":"Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients","volume":"93","author":"Passamonti","year":"2008","journal-title":"Haematologica."},{"key":"B32","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1055\/s-2006-942762","article-title":"Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia","volume":"32","author":"Kiladjian","year":"2006","journal-title":"Semin Thromb Hemost."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2020-206570","article-title":"Mutational profiling in suspected triple-negative essential thrombocythaemia using targeted next-generation sequencing in a real-world cohort","author":"Michail","year":"2020","journal-title":"J Clin Pathol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N Engl J Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/sj.leu.2404914","article-title":"Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment","volume":"22","author":"Barosi","year":"2008","journal-title":"Leukemia."},{"key":"B36","first-page":"127","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"key":"B37","first-page":"215","article-title":"Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation","volume":"89","author":"Barbui","year":"2004","journal-title":"Haematologica."},{"key":"B38","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1038\/s41375-019-0378-z","article-title":"European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms","volume":"33","author":"Rack","year":"2019","journal-title":"Leukemia."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e221","DOI":"10.3324\/haematol.2019.230193","article-title":"Disease progression in myeloproliferative neoplasms: comparing patients in accelerated phase with those in chronic phase with increased blasts (<10%) or with other types of disease progression","volume":"105","author":"Geyer","year":"2020","journal-title":"Haematologica."},{"key":"B42","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","article-title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv."},{"key":"B43","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/bjh.16380","article-title":"Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera","volume":"189","author":"Tefferi","year":"2020","journal-title":"Br J Haematol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"E264","DOI":"10.1002\/ajh.25580","article-title":"Diagnostic and prognostic contribution of targeted NGS in patients with triple-negative myeloproliferative neoplasms","volume":"94","author":"Acha","year":"2019","journal-title":"Am J Hematol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1182\/blood-2017-04-777029","article-title":"DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions","volume":"130","author":"Buscarlet","year":"2017","journal-title":"Blood."},{"key":"B46","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1182\/blood-2017-02-769869","article-title":"Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly","volume":"130","author":"Zink","year":"2017","journal-title":"Blood."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.3390\/cancers12082194","article-title":"Next generation sequencing in MPNs. Lessons from the past and prospects for use as predictors of prognosis and treatment responses","volume":"12","author":"Skov","year":"2020","journal-title":"Cancers."},{"key":"B48","doi-asserted-by":"publisher","first-page":"4665","DOI":"10.18632\/oncotarget.1941","article-title":"Identification of kit(M541L) somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response","volume":"5","author":"Iurlo","year":"2014","journal-title":"Oncotarget."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.3390\/ijms20081839","article-title":"Blast transformation in myeloproliferative neoplasms: risk factors, biological findings, and targeted therapeutic options","volume":"20","author":"Iurlo","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B50","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood."},{"key":"B51","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.exphem.2020.01.002","article-title":"ASXL1 mutation in clonal hematopoiesis","volume":"83","author":"Fujino","year":"2020","journal-title":"Exp Hematol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.3324\/haematol.2019.235994","article-title":"Clonal hematopoietic mutations linked to platelet traits and the risk of thrombosis or bleeding","volume":"105","author":"Veninga","year":"2020","journal-title":"Haematologica."},{"key":"B53","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/ajh.24973","article-title":"Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms","volume":"93","author":"Venton","year":"2018","journal-title":"Am J Hematol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/modpathol.2016.182","article-title":"The myeloproliferative neoplasms, unclassifiable: clinical and pathological considerations","volume":"30","author":"Gianelli","year":"2017","journal-title":"Mod Pathol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"E48","DOI":"10.1002\/ajh.24657","article-title":"Impact of the 2016 revised WHO criteria for myeloproliferative neoplasms, unclassifiable: Comparison with the 2008 version","volume":"92","author":"Iurlo","year":"2017","journal-title":"Am J Hematol."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.637116\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T02:10:57Z","timestamp":1615515057000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.637116\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,12]]},"references-count":55,"alternative-id":["10.3389\/fonc.2021.637116"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.637116","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,12]]},"article-number":"637116"}}